A Study of Crenezumab Versus Placebo in Preclinical PSEN1 E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer Disease (AD), Including a Placebo-Treated Noncarrier Cohort

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2015 by Genentech, Inc.
Banner Alzheimer's Institute
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Genentech, Inc.
ClinicalTrials.gov Identifier:
First received: November 22, 2013
Last updated: November 23, 2015
Last verified: November 2015
This randomized, double-blind, placebo-controlled, parallel group, adaptive study will evaluate the efficacy and safety of crenezumab versus placebo in individuals who carry the PSEN1 E280A autosomal-dominant mutation and do not meet the criteria for mild cognitive impairment due to AD or dementia due to AD and are, thus, in a preclinical phase of AD. Participants will be randomized 1:1 to receive either crenezumab or placebo subcutaneously every 2 weeks for 260 weeks. The study also includes a cohort of PSEN1 E280A mutation noncarriers who will be dosed with placebo only.

Condition Intervention Phase
Alzheimer Disease
Drug: Crenezumab
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled Parallel-Group Study in Preclinical PSEN1 E280A Mutation Carriers Randomized to Crenezumab or Placebo, and in Nonrandomized, Placebo-Treated Noncarriers From the Same Kindred, to Evaluate the Efficacy and Safety of Crenezumab in the Treatment of Autosomal-Dominant Alzheimer's Disease

Resource links provided by NLM:

Further study details as provided by Genentech, Inc.:

Primary Outcome Measures:
  • Change on Alzheimer's Prevention Initiative (API) Composite Cognitive Test total score (including Word List: Recall, Multilingual Naming Test, MMSE, Consortium to Establish a Registry for AD [CERAD] Constructional Praxis, Raven's Progressive Matrices) [ Time Frame: from baseline to Week 260 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of participants with adverse events and serious adverse events [ Time Frame: 260 weeks ] [ Designated as safety issue: No ]
  • Time to progression to mild cognitive impairment (MCI) due to AD or to dementia due to AD [ Time Frame: 260 weeks ] [ Designated as safety issue: No ]
  • Time to Clinical Dementia Rating (CDR) global score of >0 [ Time Frame: 260 weeks ] [ Designated as safety issue: No ]
  • Change in CDR Scale-Sum of boxes [ Time Frame: from baseline to Week 260 ] [ Designated as safety issue: No ]
  • Change in episodic memory measure: Free and Cued Selective Reminding Task (FCSRT) [ Time Frame: from baseline to Week 260 ] [ Designated as safety issue: No ]
  • Change in measure of overall neurocognitive functioning: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) [ Time Frame: from baseline to Week 260 ] [ Designated as safety issue: No ]
  • Change in mean cerebral fibrillar amyloid accumulation [ Time Frame: from baseline to Week 260 ] [ Designated as safety issue: No ]
  • Change in regional cerebral metabolic rate of glucose (CMRrI) [ Time Frame: from baseline to Week 260 ] [ Designated as safety issue: No ]
  • Change in brain atrophy measured by volumetric measurements using MRI [ Time Frame: from baseline to Week 260 ] [ Designated as safety issue: No ]
  • Change in a tau-based cerebral spinal fluid biomarker [ Time Frame: from baseline to Week 260 ] [ Designated as safety issue: No ]
  • Number of participants with anti-crenezumab antibodies [ Time Frame: 260 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 300
Study Start Date: December 2013
Estimated Study Completion Date: September 2020
Estimated Primary Completion Date: September 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Mutation Carriers: Crenezumab
Participants will receive crenezumab subcutaneously every 2 weeks.
Drug: Crenezumab
Crenezumab will be administered subcutaneously every 2 weeks.
Placebo Comparator: Mutation Carriers: Placebo
Participants will receive placebo subcutaneously every 2 weeks.
Drug: Placebo
Placebo will be administered subcutaneously every 2 weeks.
Placebo Comparator: Noncarriers of Mutation: Placebo
Participants will receive placebo subcutaneously every 2 weeks.
Drug: Placebo
Placebo will be administered subcutaneously every 2 weeks.


Ages Eligible for Study:   30 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult participants, greater than or equal to (>=) 30 and less than or equal to (<=) 60 years of age
  • Membership in PSEN1 E280A mutation carrier kindred
  • Agrees to conditions of, and is willing to undergo, genetic testing (e.g., apolipoprotein E [APOE], PSEN1 E280A, and other genetic testing)
  • PSEN1 E280A mutation carrier or noncarrier status has been confirmed prior to or during the screening period
  • Mini-Mental Stage Examination (MMSE) >= 24 for participants with less than (<) 9 years of education or MMSE >=26 for participants with 9 or more years of education
  • Does not meet criteria for dementia due to AD (McKhann 2011)
  • Does not meet criteria for mild cognitive impairment (MCI) due to AD (Albert 2011)
  • Adequate vision and hearing in the investigator's judgment to be able to complete testing
  • If female, and not documented (by medical records or physician's note) to be surgically sterile (absence of ovaries and/or uterus) or postmenopausal, willing to undergo pregnancy tests at protocol-specific timepoints
  • For women who are not documented (by medical records or physician's note) to be surgically sterile (absence of ovaries and/or uterus) or postmenopausal, agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of < 1% per year (e.g., hormonal implants, combined oral contraceptives, vasectomized partner, tubal ligation) during the treatment period and for at least 16 weeks after the last dose of study drug
  • For men with partners of childbearing potential (i.e., women who are not surgically sterile and are not postmenopausal, agreement to remain abstinent or use a condom as a method of contraception during the treatment period and for at least 8 weeks after the last dose of study drug
  • Study partner who agrees to participate in the study and is capable of and willing to:
  • Accompany the participant to all required visits
  • Provide information for required telephone assessments
  • Spend sufficient time with the participant to be familiar with his/her overall function and behavior and be able to provide adequate information about the participant including knowledge about domestic activites, hobbies, routines, social skills and basic acivities of daily life; work and educational history; cognitive performance including memory abilities, language abilities, temporal and spatial orientation, judgement and problem solving; emotional and psychological state; and general health status
  • Participant and study partner have evidence of adequate premorbid functioning (e.g., intellectual, visual, and auditory)
  • Participant and study partner are fluent in, and able to read, the language in which study assessments are administered
  • Willing and able to undergo neuroimaging (positron emission tomography [PET] and magnetic resonance imaging [MRI])
  • Serum thyroid stimulating hormone (TSH) and B12 levels within normal or expected ranges for the testing laboratory or TSH and B12 values out of range that are judged by the investigator not to be clinically significant If participant is undergoing thyroid replacement therapy, TSH levels must be normal or expected ranges for the testing laboratory If participant is receiving vitamin B12 injections or oral vitamin B12 therapy, B12 levels must be at or above the lower limit of normal for the testing laboratory
  • In good general health with no known co-morbidities expected to interfere with participation in the study

Exclusion Criteria:

  • Significant medical, psychiatric, or neurological condition or disorder documented by history, physical, neurological, laboratory, or electrocardiogram (ECG) examination that would place the participant at undue risk in the investigator's judgment or impact the interpretation of efficacy
  • History of stroke Participants with a history of transient ischemic attack may be enrolled if the event occurred >=2 years prior to screening
  • History of severe, clinically significant (persistent neurological deficit or structural brain damage) central nervous system trauma (e.g. cerebral contusion)
  • Body weight <45 or >120 kilogram (kg)
  • History or presence of atrial fibrillation that poses a risk for future stroke in the investigator's judgment
  • Clinically significant laboratory or ECG abnormalities (e.g., abnormally prolonged or shortened QTc interval) in the investigator's judgment
  • Current presence of bipolar disorder or other clinically significant major psychiatric disorder according to Diagnostic and Statistical Manual of Mental Disorders 4th Edition Text Revision (DSM-IV-TR) or symptom (e.g., hallucinations, agitation, paranoia) that could affect the participant's ability to complete evaluations
  • Geriatric Depression Scale (short form) (15-point scale) score >9 at screening
  • History of seizures (excluding febrile seizures of childhood, or other isolated seizure episodes that were not due to epilepsy in the judgment of the investigator, and required at most time-limited anticonvulsant treatment, and which occurred more than 7 years prior to the screening visit)
  • Myocardial infarction within 2 years, congestive heart failure, atrial fibrillation, or uncontrolled hypertension
  • Pregnant or nursing women, or women who intend to become pregnant or to nurse infants during the conduct of this trial
  • Clinically significant infection within the last 30 days prior to screening
  • Positive urine test for drugs of abuse at screening
  • History of alcohol or substance dependence within the previous two years
  • Use of any other medications with the potential to significantly affect cognition
  • Use of typical anti-psychotics, barbiturates, or anti-cholinergic antidepressants unless used in low doses for conditions other than depression, such as migraine headaches, and approved by the medical monitor
  • Use of non-anti-cholinergic antidepressant medications or atypical anti-psychotics unless maintained on a stable dose regimen for at least 6 weeks prior to screening
  • Use of any Food and Drug Administration (FDA)/Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA)-approved medications for treatment of late onset Alzheimer's disease (LOAD) at screening/baseline Cholinesterase inhibitors and/or memantine are prohibited during the study except in participants enrolled in the study that develop AD dementia.
  • Use of anti-coagulant medication, except aspirin (heparinoids, heparin, warfarin, thrombin inhibitors, Factor Xa inhibitors), or known coagulopathy or platelet count <100,000 cells/mcL, within 4 weeks of the screening visit
  • Treatment with any biologic therapy within five half-lives or 3 months prior to screening, whichever is longer, with the exception of routinely recommended vaccinations, which are allowed
  • Use of anti-seizure medication (except in childhood for febrile seizures or if used for non-seizure indications), anti-parkinsonian, or stimulant (e.g., methylphenidate) medications
  • Use of investigational drug, device, or experimental medication within 60 days (or five half-lives, whichever is longer) of the screening visit
  • Previous treatment with crenezumab (MABT5102A) or any other therapeutic that targets A beta
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins
  • Contraindication to MRI scan procedures or clinically significant claustrophobia that would contraindicate a brain MRI scan
  • Contraindication to PET scan procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01998841

Contact: Reference Study ID Number: GN28352 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. Only) global.rochegenentechtrials@roche.com

Medellin, Colombia
Yarumal, Colombia
Sponsors and Collaborators
Genentech, Inc.
Banner Alzheimer's Institute
National Institute on Aging (NIA)
Study Director: Clinical Trials Genentech, Inc.
  More Information

No publications provided

Responsible Party: Genentech, Inc.
ClinicalTrials.gov Identifier: NCT01998841     History of Changes
Other Study ID Numbers: GN28352
Study First Received: November 22, 2013
Last Updated: November 23, 2015
Health Authority: INVIMA: Instituto Nacional de Vigilancia de Medicamentos y Alimentos

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on November 27, 2015